Evidence map›Paper›PMID 38184548›Full record

ArticleImplementation science : IS2024

Influence of physician networks on the implementation of pharmaceutical alternatives to a toxic drug supply in British Columbia.

Megan Kurz, Brenda Carolina Guerra-Alejos, Jeong Eun Min, Brittany Barker, Bernadette Pauly, Karen Urbanoski, Bohdan Nosyk

Open access · goldAbstract read
In one paragraph

Article in Implementation science : IS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
16.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Perceived impacts of North Americas first de-medicalized safer supply program.Substance abuse treatment, prevention, and policy · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Megan KurzCentre for Advancing Health Outcomes, Vancouver, BC, Canada.
Brenda Carolina Guerra-AlejosCentre for Advancing Health Outcomes, Vancouver, BC, Canada.
Jeong Eun MinCentre for Advancing Health Outcomes, Vancouver, BC, Canada.
Brittany BarkerFaculty of Health Sciences, Simon Fraser University, Burnaby, V5A 1S6, Canada.
Bernadette PaulyDepartment of Nursing, University of Victoria, Victoria, BC, Canada.
Karen UrbanoskiSchool of Public Health and Social Policy, University of Victoria, Victoria, BC, Canada.
Bohdan NosykCentre for Advancing Health Outcomes, Vancouver, BC, Canada. bnosyk@sfu.ca.ORCID 0000-0003-2513-3718
Simon Fraser University · CACentre for Advancing Health Outcomes · CAUniversity of Victoria · CA

Funding

DAT-Emulating target trials with big data to strengthen the evidence base for the clinical management of opioid use disorderR01DA050629 · NIDA · SIMON FRASER UNIVERSITY · PI NOSYK, BOHDAN · 2021 to 2025
$2.4M
CIHR PJT-180412NIDA NIH HHS R01 DA050629
6 · The paper itself

Abstract

backgroundCharacterizing the diffusion of adopted changes in policy and clinical practice can inform enhanced implementation strategies to ensure prompt uptake in public health emergencies and other rapidly evolving disease areas. A novel guidance document was introduced at the onset of the COVID-19 pandemic in British Columbia (BC), Canada, which supported clinicians to prescribe opioids, stimulants, and benzodiazepines. We aimed to determine the extent to which uptake and discontinuation of an initial attempt at a prescribed safer supply (PSS) program were influenced through networks of prescribers.

methodsWe executed a retrospective population-based study using linked health administrative data that captured all clinicians who prescribed to at least one client with a substance use disorder from March 27, 2020, to August 31, 2021. Our main exposure was the prescribing patterns of an individuals' peers, defined as the proportion of a prescribers' professional network (based on shared clients), which had previously prescribed PSS, updated monthly. The primary outcome measured whether a clinician had prescribed their initial PSS prescription during a given calendar month. The secondary outcome was the discontinuation of PSS prescribing, defined as an absence for PSS prescriptions for at least 3 months. We estimated logistic regression models using generalized estimated equations on monthly repeated measurements to determine and characterize the extent to which peer networks influenced the initiation and discontinuation of PSS prescribing, controlling for network, clinician, and caseload characteristics. Innovators were defined as individuals initiating PSS prior to May 2020, and early adopters were individuals initiating PSS after.

resultsAmong 14,137 prescribers treating clients with substance use disorder, there were 228 innovators of prescribed safer supply and 1062 early adopters through the end of study follow-up, but 653 (50.6%) were no longer prescribing by August 2021. Prescribers with over 20% of peers whom had adopted PSS had a nearly fourfold higher adjusted odds of PSS prescribing themselves (aOR: 3.79, 95% CI: (3.15, 4.56)), compared to those with no connected safer supply prescribers.

conclusionsThe uptake of PSS in BC was highly dependent on the behavior of prescribers' peer networks. Future implementation strategies to support PSS or other policies would benefit from leveraging networks of prescribers.

Indexed as

PandemicsSubstance-Related DisordersBritish ColumbiaHumansPharmaceutical PreparationsRetrospective StudiesPharmaceutical PreparationsImplementation sciencePrescribed safer supplySocial network analysisSubstance use disorder

Identifiers

PMID38184548
PMCPMC10771688
OpenAlexW4390640343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.